Prevention and Early Treatment of Acute Lung Injury (PETAL) Network – Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study (BLUE CORAL) - Catalog
Prevention and Early Treatment of Acute Lung Injury (PETAL) Network – Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study (BLUE CORAL)
HLB02732323a
PETAL-BLUE CORAL
(PETAL-FIRE CORAL) Prevention and Early Treatment of Acute Lung Injury (PETAL) Network – Functional, imaging, and respiratory evaluation in CORAL (FIRE CORAL)
(PETAL-RED CORAL) Prevention and Early Treatment of Acute Lung Injury (PETAL) Network - Repository of Electronic Data COVID-19 Observational Study (RED CORAL)
PBC
False
COVID-19
SARS-CoV-2
True
True
Coded
https://petalnet.org/studies.html
False
Epidemiology Study
Open BioLINCC Study
Adult
2023-07-05
2023-12-05
2023-07-05
None
June 2020 to March 2022
DLD
Lung
non-HIV
COVID
None
71
No
No
Yes
Yes
Yes, For Some Specimens
Yes
Use of specimens in non-genetic and/or genetic research is tiered to 1) research related to COVID-19 and/or 2) research involved with other medical conditions. Specimens may not be used directly to produce commercial products.
Corona Virus Infection
SARS-CoV Infection
To measure the incidence and changes over time in symptoms, disability, and financial status after COVID-19–related hospitalization.
For many individuals, the effects of COVID-19 persist after the acute phase and result in prolonged symptoms and disability. This has led to widespread efforts to characterize the epidemiologic characteristics of such post-COVID-19 sequelae. However, accurate data were limited, hindering the ability to counsel patients, caregivers, and policy makers and to plan relevant recovery-focused clinical research. Thus, the BLUE CORAL study was intended to address the knowledge gaps and provide critical data to help guide clinical care, public health, and scientific efforts.
Participants included English- or Spanish-speaking adults that were hospitalized at one of the 44 PETAL Network hospitals across the U.S. within 14 days of a positive molecular test for SARS-CoV-2 with fever and/or respiratory signs or symptoms compatible with COVID-19. Patients were enrolled within the first 72 hours of hospital admission and were excluded if they had opted for comfort care, were incarcerated, or had severe prehospitalization disabilities or cognitive impairment.
A total of 1388 COVID-19 patents were enrolled, with 825 (444 male, and 379 female) that completed at least one follow-up survey.
A subset of the BLUE CORAL adult participants were enrolled in the extension study, FIRE CORAL. FIRE CORAL was a multicenter prospective cohort study of participants recovering from COVID-19 disease after discharge from the hospital.
BLUE CORAL was a prospective cohort study. Participants were enrolled between August 24, 2020, and July 20, 2021, with follow-up occurring through March 30, 2022. Posthospital surveys were administered by trained interviewers in English or Spanish to patients or their proxies at 1, 3, and 6 months after enrollment. Cardiopulmonary symptoms were assessed using the Airways Questionnaire 20, the Kansas City Cardiomyopathy Questionnaire, and the Seattle Angina Questionnaire. Fatigue was assessed using the Patient Health Questionnaire-9. Disability was assessed by self-report of limitations in activities of daily living (ADLs) or instrumental activities of daily living (IADLs). Financial problems were assessed using the World Health Organization Disability Assessment Schedule 2.0 question and questions regarding job changes, time off work, and insurance coverage developed with the Mi-COVID-19 study using qualitative interviews. Quality of life was measured using the European Quality of Life 5-dimension 5-level instrument.
The primary outcomes were new or worsened cardiopulmonary symptoms, financial problems, functional impairments, perceived return to baseline health, and quality of life. Symptoms that were not present before hospitalization or specifically reported as increased in severity were counted as new or worsened.
The findings of this cohort study of people discharged after COVID-19 hospitalization suggest that recovery in symptoms, functional status, and fatigue was limited at 6 months, and some participants reported new problems 6 months after hospital discharge.
Admon AJ, Iwashyna TJ, Kamphuis LA, Gundel SJ, Sahetya SK, Peltan ID, Chang SY, Han JH, Vranas KC, Mayer KP, Hope AA, Jolley SE, Caldwell E, Monahan ML, Hauschildt K, Brown SM, Aggarwal NR, Thompson BT, Hough CL; National Heart, Lung, and Blood Institute PETAL Network. Assessment of Symptom, Disability, and Financial Trajectories in Patients Hospitalized for COVID-19 at 6 Months. JAMA Netw Open. 2023 Feb 1;6(2):e2255795. doi: 10.1001/jamanetworkopen.2022.55795. PMID: 36787143; PMCID: PMC9929698.
Bronchial Lavage
Plasma
Tracheal Aspirate
Urine
Whole Blood
The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.
-
Subjects
1,375 Subjects
Last Modified: March 18, 2024, 10:27 a.m. -
Age
-
Sex
Total Subjects
Male
741
Female
634
Last Modified: March 18, 2024, 10:27 a.m. -
Race
Total Subjects
BLACK
253
HISPANIC
385
MISSING/UNKNOWN/REFUSED
58
OTHER
63
WHITE
616
Last Modified: March 18, 2024, 10:27 a.m.
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
-
Material Types
Plasma, Whole blood for the purpose of DNA extraction, Whole blood for the purpose of RNA extraction, Urine, BAL, Sputum
Last Modified: March 18, 2024, 10:27 a.m. -
General Freeze/Thaw Status
03/18/2024
All specimens are unthawed
Last Modified: March 18, 2024, 10:27 a.m. -
Visits (Vials)
03/18/2024
Plasma
Whole Blood, DNA Extraction
Whole Blood, RNA Extraction
Urine
Bronchoalveolar Lavage (BAL)
Sputum
Total Vials
Floor Draw
2,123
544
549
.
.
.
3,216
ICU Draw A
873
192
194
588
175
30
2,052
ICU Draw B
634
138
140
.
.
.
912
ICU Draw C
364
75
78
.
.
.
517
ICU Draw D
279
55
56
.
.
.
390
ICU Draw E
193
39
41
.
.
.
273
Last Modified: March 18, 2024, 10:30 a.m. -
Visits (Subjects)
03/18/2024
Plasma
Total number of subjects
Average volume (mL) per subject
Floor Draw
534
1.05
ICU Draw A
195
1.19
ICU Draw B
137
1.32
ICU Draw C
78
1.33
ICU Draw D
57
1.29
ICU Draw E
39
1.43
Urine
Total number of subjects
Average volume (mL) per subject
ICU Draw A
99
7.83
Bronchoalveolar Lavage (BAL)
Total number of subjects
Average volume (mL) per subject
ICU Draw A
36
4.29
Sputum
Total number of subjects
Average volume (mL) per subject
ICU Draw A
20
1.18
Whole Blood, DNA Extraction
Total number of subjects
Average volume (mL) per subject
Floor Draw
544
2.33
ICU Draw A
192
2.41
ICU Draw B
138
2.49
ICU Draw C
75
2.45
ICU Draw D
55
2.45
ICU Draw E
39
2.28
Whole Blood, RNA Extraction
Total number of subjects
Average volume (mL) per subject
Floor Draw
549
7.23
ICU Draw A
194
7.48
ICU Draw B
140
7.45
ICU Draw C
78
7.53
ICU Draw D
56
7.63
ICU Draw E
41
7.43
Last Modified: March 18, 2024, 10:30 a.m.